Skip to Content
Merck
All Photos(1)

Documents

P1800000

Pindolol

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

1-(1H-Indol-4-yloxy)-3-(isopropylamino)-2-propanol, 1-(1H-Indol-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C14H20N2O2
CAS Number:
13523-86-9
Molecular Weight:
248.32
MDL number:
MFCD00010530
UNSPSC Code:
41116107
PubChem Substance ID:
329820108
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

pindolol

manufacturer/tradename

EDQM

mp

167-171 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC(C)NCC(O)COc1cccc2[nH]ccc12

InChI

1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3

InChI key

JZQKKSLKJUAGIC-UHFFFAOYSA-N

Gene Information

human ... ADRB1(153) , ADRB2(154)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Pindolol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

β1-adrenoceptor antagonist; putative 5-HT1A serotonin receptor agonist; vasodilator.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302,H315,H319,H335

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

G G Kinney et al.
Molecular neurobiology, 21(3), 137-152 (2001-05-31)
The development of selective serotonin reuptake inhibitors (SSRIs) provided a major advancement in the treatment of depression. However, these drugs suffer from a variety of drawbacks, most notably a delay in the onset of efficacy. One hypothesis suggests that this
Rebecca Segrave et al.
Human psychopharmacology, 20(3), 163-174 (2005-01-14)
Co-administration of pindolol with SSRIs in patients with depression has been suggested as a way to both hasten and augment antidepressant response. Clinical trials have examined the efficacy of this treatment regime and conflicting results have been reported. The present
A Fanchamps
American heart journal, 104(2 Pt 2), 388-406 (1982-08-01)
The antihypertensive effect of pindolol has been demonstrated in several hundred clinical trials performed in many countries. The results of several representative trials will be reviewed in this article. In a cooperative study of pindolol by Swiss internists, blood pressure
Francesc Artigas et al.
Current drug targets, 7(2), 139-147 (2006-02-16)
Pindolol, a partial beta-adrenoceptor/5-HT1A receptor antagonist was first used to accelerate the onset of action of antidepressant drugs in 1994. Since then, it has been used in more than a dozen controlled trials to examine whether it can reduce the
D Martinez et al.
Biological psychiatry, 48(8), 844-853 (2000-11-07)
Preclinical studies suggest that augmentation of selective serotonin (5-HT) reuptake inhibitors by the 5-HT(1A) receptor agent pindolol might reduce the delay between initiation of treatment and antidepressant response, an effect largely mediated by blockade of 5-HT(1A) autoreceptors in the dorsal
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service